Filing Details

Accession Number:
0001209191-15-009196
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-02-03 20:55:10
Reporting Period:
2015-01-30
Filing Date:
2015-02-03
Accepted Time:
2015-02-03 20:55:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
69499 Mylan Inc. MYL Pharmaceutical Preparations (2834) 251211621
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1248380 F Neil Dimick 1000 Mylan Blvd
Canonsburg PA 15317
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-01-30 5,400 $21.00 43,987 No 4 M Direct
Common Stock Disposition 2015-01-30 5,400 $53.73 38,587 No 4 S Direct
Common Stock Acquisiton 2015-02-02 7,758 $21.00 46,345 No 4 M Direct
Common Stock Acquisiton 2015-02-02 682 $31.63 47,027 No 4 M Direct
Common Stock Disposition 2015-02-02 8,440 $52.87 38,587 No 4 S Direct
Common Stock Acquisiton 2015-02-03 5,941 $31.63 44,528 No 4 M Direct
Common Stock Disposition 2015-02-03 5,941 $53.01 38,587 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Employee Director Stock Option - Right to Buy Disposition 2015-01-30 5,400 $0.00 5,400 $21.00
Common Stock Non-Employee Director Stock Option - Right to Buy Disposition 2015-02-02 7,758 $0.00 7,758 $21.00
Common Stock Non-Employee Director Stock Option - Right to Buy Disposition 2015-02-02 682 $0.00 682 $31.63
Common Stock Non-Employee Director Stock Option - Right to Buy Disposition 2015-02-03 5,941 $0.00 5,941 $31.63
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
7,758 2022-05-04 No 4 M Direct
0 2022-05-04 No 4 M Direct
5,941 2023-05-28 No 4 M Direct
0 2023-05-28 No 4 M Direct
Footnotes
  1. Represents acquisition of Mylan common stock upon exercise of stock options granted on May 4, 2012.
  2. Represents the weighted average price of shares sold by the broker on behalf of certain non-employee directors and executive officers of Mylan on January 30, 2015. The broker sold, in the aggregate on behalf of such non-employee directors and executive officers, 403,595 shares in transactions ranging from $53.01 to $54.00 with a weighted average price of $53.5684 as well as 205,341 shares in transactions ranging from $54.005 to $54.25 with a weighted average price of $54.0425. The proceeds of all such sales were allocated to the applicable non-employee directors and executive officers on a pro rata basis based on the number of shares sold by such person.
  3. Represents acquisition of Mylan common stock upon exercise of stock options granted on May 28, 2013.
  4. Represents the weighted average price of shares sold by the broker on behalf of certain non-employee directors and executive officers of Mylan on February 2, 2015. The broker sold, in the aggregate on behalf of such non-employee directors and executive officers, 937,763 shares in transactions ranging from $52.23 to $53.22 with a weighted average price of $52.8646 as well as 13,957 shares in transactions ranging from $53.23 to $53.745 with a weighted average price of $53.5027. The proceeds of all such sales were allocated to the applicable non-employee directors and executive officers on a pro rata basis based on the number of shares sold by such person.
  5. Represents the weighted average price of shares sold by the broker on behalf of certain non-employee directors and executive officers of Mylan on February 3, 2015. The broker sold, in the aggregate on behalf of such non-employee directors and executive officers, 520,475 shares in transactions ranging from $52.50 to $53.25 with a weighted average price of $52.8739 as well as 149,400 shares at $53.50 and 1 share at $54.50. The proceeds of all such sales were allocated to the applicable non-employee directors and executive officers on a pro rata basis based on the number of shares sold by such person.
  6. This option exercise and the related sale of the underlying common stock were executed pursuant to a 10b5-1 trading plan dated November 9, 2014.
  7. These options vested in full on May 4, 2013.
  8. These options vested in full on May 28, 2014.